

Supplemental Table S3. Baseline Parameters Affecting Both Glucose-Lowering and the Weight-Reducing Effect of Dapagliflozin

Variable	OR (95% CI) ^a	P value
Age, yr	0.95 (0.87–1.04)	0.240
Male sex	2.50 (0.52–12.50)	0.251
DM duration, yr	0.81 (0.68–0.97)	0.023
Weight, kg	1.01 (0.94–1.08)	0.796
BMI, kg/m ²	0.96 (0.75–1.24)	0.774
WC, cm	0.96 (0.86–1.07)	0.435
Fat %	0.97 (0.86–1.08)	0.547
Fat mass, kg	0.97 (0.86–1.11)	0.698
Lean mass, kg	1.01 (0.92–1.11)	0.804
VAT, cm ²	1.00 (0.98–1.02)	0.673
SAT, cm ²	1.00 (0.99–1.01)	0.651
Systolic BP, mm Hg	1.01 (0.95–1.09)	0.686
Diastolic BP, mm Hg	1.03 (0.92–1.15)	0.600
HbA1c, %	1.59 (0.37–6.81)	0.536
FPG, mg/dL	1.01 (0.98–1.04)	0.572
TG, mg/dL	1.00 (0.99–1.01)	0.864
HDL-C, mg/dL	0.96 (0.90–1.03)	0.297
LDL-C, mg/dL	1.00 (0.98–1.03)	0.823
TG/HDL	1.15 (0.76–1.73)	0.506
AST, U/L	1.00 (0.94–1.06)	0.962
ALT, U/L	1.00 (0.97–1.04)	0.860
eGFR, mL/min/1.73 m ²	1.04 (0.98–1.12)	0.223
Log adiponectin, µg/mL	0.44 (0.03–6.55)	0.548
Log hs-CRP, mg/dL	1.85 (0.26–13.23)	0.540

OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; BMI, body mass index; WC, waist circumference; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; BP, blood pressure; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein.

^aReference as group 4.